Prostatic Neoplasms, Castration-Resistant

4 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.

Broader: Neoplasms, Prostatic Neoplasms

Treatments and conditions

Prostatic Neoplasms, Castration-Resistant
Treatment and conditionWhere it standsTrials
Androgen receptor signaling inhibitor (ARSI) + VIR-5500 for prostatic neoplasms, castration-resistantPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Androgen receptor signaling inhibitor (ARSI) + VIR-5500 + DOCETAXEL for prostatic neoplasms, castration-resistantPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Omeprazole 80 mg twice daily for prostatic neoplasms, castration-resistantPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
VIR-5500 for prostatic neoplasms, castration-resistantPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1

Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.